US breast cancer patient registry study: CAPTURE (Compliance and Preference for Tamoxifen Registry)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Mar 2014
At a glance
- Drugs Tamoxifen (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms CAPTURE
- Sponsors Midatech Pharma US
- 13 Mar 2014 Status changed from recruiting to active, no longer recruiting based on information reported in a DATA BioSciences media release.
- 13 Mar 2014 Results will be presented at the National Comprehensive Cancer Network (NCCN) 19th Annual Conference: Advancing the Standard of Cancer Care according to a DARA BioSciences media release. Results were also reported in the media release.
- 14 Aug 2013 DARA BioSciences has enrolled 13 US oncology centres and completed nearly 50% of the patient surveys in this registry, according to a company media release.